53.24
0.74 (1.42%)
| Previous Close | 52.49 |
| Open | 52.85 |
| Volume | 522,983 |
| Avg. Volume (3M) | 1,034,127 |
| Market Cap | 2,922,164,992 |
| Price / Sales | 7.30 |
| Price / Book | 5.36 |
| 52 Weeks Range | |
| Earnings Date | 25 Feb 2025 |
| Profit Margin | -36.20% |
| Operating Margin (TTM) | -39.67% |
| Diluted EPS (TTM) | -1.69 |
| Quarterly Revenue Growth (YOY) | 55.30% |
| Total Debt/Equity (MRQ) | 21.02% |
| Current Ratio (MRQ) | 8.95 |
| Operating Cash Flow (TTM) | -83.91 M |
| Levered Free Cash Flow (TTM) | -58.77 M |
| Return on Assets (TTM) | -13.36% |
| Return on Equity (TTM) | -27.62% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | PROCEPT BioRobotics Corporation | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | 1.5 |
| Price Volatility | 2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 1.30 |
|
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System,, image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. The company's assets are based in the United States. Its revenue is generated from sales of the AquaBeam Robotic System and the accompanying single-use disposable handpieces. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Growth |
| % Held by Insiders | 4.22% |
| % Held by Institutions | 93.06% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 68.00 (Morgan Stanley, 27.74%) | Buy |
| Median | 59.00 (10.83%) | |
| Low | 55.00 (Piper Sandler, 3.32%) | Buy |
| Average | 60.25 (13.18%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 44.19 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Oppenheimer | 02 Sep 2025 | 60.00 (12.71%) | Buy | 39.57 |
| Piper Sandler | 07 Aug 2025 | 55.00 (3.32%) | Buy | 39.59 |
| Wells Fargo | 07 Aug 2025 | 58.00 (8.95%) | Buy | 39.59 |
| Morgan Stanley | 15 Jul 2025 | 68.00 (27.74%) | Buy | 58.01 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 06 Aug 2025 | Announcement | PROCEPT BioRobotics Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance |
| 24 Jul 2025 | Announcement | PROCEPT BioRobotics® President and CEO Dr. Reza Zadno to Retire, Company Appoints Larry L. Wood as New President and CEO |
| 23 Jul 2025 | Announcement | Ambulatory Surgery Center Completes WATER IV Trial Procedures for Prostate Cancer with Aquablation® Therapy |
| 21 Jul 2025 | Announcement | PROCEPT BioRobotics® to Report Second Quarter 2025 Financial Results on August 6, 2025 |
| 14 Jul 2025 | Announcement | Aquablation® Therapy’s Assigned Category I Code in 2026 Medicare Proposed Physician Fee Schedule |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |